



1653 /Image

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SVANBORG, C. et al.

Atty. Ref.: 2491-49

Serial No. 10/506,903

Group: Unassigned

Filed: September 7, 2004

Examiner: Unassigned

For: BIOLOGICALLY ACTIVE COMPLEX

\* \* \* \* \*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

June 14, 2005

Sir:

**INFORMATION DISCLOSURE STATEMENT**

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**  
[within 3 months of filing or prior to 1st Office Action on the merits] N/C
- 2.(a) **Statement Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)] N/C
- 2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**  
[before Final Office Action or Allowance (requires Rule 97(e)  
Statement or Rule 17(p) fee)] \$180.00
3. **Pursuant to 37 CFR 1.97(d)**  
[after Final Office Action or Allowance (requires Rule 97(e)  
Statement and Rule 17(p) fee), but before final fee payment]  
\$180.00

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.


This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]
6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and
- a) The required Statement made in item 8 below; or
- b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.
7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and
- a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and
- b) The required Statement is stated in item 8 below.
8. Statement under 37 CFR 1.97(e)
- a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or
- b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,  
NIXON & VANDERHYE P.C.

By: \_\_\_\_\_



B. J. Sadoff

Reg. No. 36,663

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**INFORMATION DISCLOSURE**

ATTY. DOCKET NO.

SERIAL NO.

**CITATION**

2491-49

10/506,903

APPLICANT

SVANBORG, C. et al.


(Use several sheets if necessary)

FILING DATE

GROUP

September 7, 2004

Unassigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,348,376	09/1982	Goldenberg			
	6,455,673	09/2002	Collier			
	5,614,191	03/1997	Puri et al			

**FOREIGN PATENT DOCUMENTS**

DOCUMENT	DATE	COUNTRY	TRANSLATION		
			CLASS	SUBCLASS	YES NO
WO 96/04929	02/1996	WIPO			
2 671 697	07/1992	France			

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

	Schwartz et al, Immunology Today, 1993, Vol. 14, No. 12, pp 582-590
	McConkey et al, Molec. Aspects Med., 1996, Vol. 17, pp 1-110
	Kerr et al, Cancer, 1994, Vol. 73, No. 8, pp 2013-2026
	Arends et al, American Journal of Pathology, 1990, Vol. 136, pp 593-608
	Zhivotovsky et al, FEBS Letters, 1994, Vol. 351, pp 150-154
	Zhivotovsky et al, Experimental Cell Research, 1995, Vol. 221, pp 404-412
	Kumar, TIBS, 1995, Vol. 20, pp 198-202
	Zheng et al, Nature, 1995, Vol. 377, pp 348-351
	Declercq et al, Cytokine, 1995, Vol. 7, No. 7, pp 701-709
	Griffith et al, Science, 1995, Vol. 270, pp 1189-1192
	Jans et al, Physiological Reviews, 1996, Vol. 76, No. 3, pp 651-685
	Gorlich et al, Science, 1996, Vol. 271, pp 1513-1518
	Yoneda, J. Biochem., 1997, Vol. 121, pp 811-817
	Yang et al, Molecular and Cellular Biology, 1994, Vol. 14, No. 8, pp 5088-5098
	Heine et al, S. Nutr., 1991, Vol. 121, pp 277-83
	Sheridan et al, Science, 1997, Vol. 277, pp 818-821
	Pan et al, Science, 1997, Vol. 277, pp 815-818
	Adam et al, The Journal of Cell Biology, 1990, Vol. 111, pp 807-816
	Garcia-Bustos et al, Biochem. Biophys. Acta, 1991, Vol. 1071, pp 83-101
	Ren et al, The Journal of Biological Chemistry, 1992, Vol. 268, No. 26, pp 19292-19298
	Kuwajima et al, FASEB J., 1996, Vol. 10, pp 102-109
	Alexandrescu et al, Biochemistry, 1993, No. 32, pp 1707-1708
	Kabara et al, Antimicrobial Agents and Chemotherapy, 1972, Vol. 2, No. 1, pp 23-28

\*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

**INFORMATION DISCLOSURE**

ATTY. DOCKET NO.

SERIAL NO.

**CITATION**

2491-49

10/506,903

APPLICANT

SVANBORG, C. et al.

(Use several sheets if necessary)

FILING DATE

GROUP

September 7, 2004

Unassigned

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

TRANSLATION

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**


Gill et al, Science, 1983, Vol. 221, pp 1290-1293
Davis et al, The Lancet, 1988, pp 365-368
Siskind et al, American Journal of Epidemiology, 1989, Vol. 130, No. 2, pp 229-236
Newcomb et al, The New England Journal of Medicine, 1994, Vol. 330, pp 81-87
Sander et al, Immunological Review, 1991, No. 119, pp 65-93
Graham, Isolation of Subcellular Organelles and Membranes, p 161-182 in D. Rickwood, ed., Centrifugation, a practical approach, 2 <sup>nd</sup> ed., IRL Press, Washington, D.C.
Hakansson et al, Experimental Cell Research, 1999, Vol. 246, pp 451-460
Hakansson et al, Proc. Nat'l. Acad. Sci., 1995, Vol. 92, pp 8064-8068
Ming, Magnetic Resonance in Chemistry, 1993, Vol. 31, pp S104-S109
Signore et al, European Journal of Endocrinology, 1994, Vol. 131, pp 431-347
Blair et al, Journal of Immunological Methods, 1983, Vol. 59, pp 129-143
Johnstone et al, Immunochemistry in Practice 2 <sup>nd</sup> Edition, Blackwell Scientific Publications Oxford, 1987, pp 113-130
Goers, Immunochemical Techniques Laboratory Manual, Academic Press, San Diego 1993, pp 69-79
Jain, Scientific American, Vol. 271, pp 58-65
Zeisel et al, J. Nutr. 1986, Vol. 116, pp 50-58
Kronman et al, Biochemistry, 1965, Vol. 4, No. 3, pp 518-525
Dolgikh et al, FEBS Letters, 1981, Vol. 136, No. 2, pp 311-315
Dolgikh et al, FEBS Letters, 1984, Vol. 165, No. 1, pp 88-92
Ohgushi et al, FEBS Letters, 1983, Vol. 164, No. 1, pp 21-24
Pfeil, Biochimica et Biophysica Acta, 1987, pp 114-116
Kuwajima, The FASEB Journal, Vol. 10, pp 102-109
Jegouic et al, J. Agric. Food Chem. 1997, No. 45, pp 19-22
Schulman et al, J. Mol. Biol., 1995, Vol. 253, pp 651-657
Bitman et al, Journal of Pediatric Gastroenterology and Nutrition, 1983, Vol. 2, No. 3, pp 521-524

\*Examiner \_\_\_\_\_ Date Considered \_\_\_\_\_

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)





Examiner

**Date Considered**

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**Form PTO-FB-A820 (Also PTO-1449)**



<b>INFORMATION DISCLOSURE CITATION</b>	ATTY. DOCKET NO.	SERIAL NO.
	2491-49	10/506,903
(Use several sheets if necessary)	APPLICANT	GROUP
	SVANBORG, C. et al.	
	FILING DATE	
	September 7, 2004	Unassigned

JUN 14 2005  
USPTO  
PATENT & TRADEMARK OFFICE

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

**OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)**

\*Examiner \_\_\_\_\_ Date Considered \_\_\_\_\_

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)

\*Examiner

---

**Date Considered**

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

**Form PTO-FB-A820 (Also PTO-1449)**